UiPath (NASDAQ:PATH – Get Rating) will announce its earnings results after the market closes on Tuesday, September 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. UiPath has set its FY 2023 guidance at EPS and its Q2 2023 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.
UiPath Stock is Nearing Rock Bottom Down Here
UiPath (NASDAQ:PATH – Get Rating) last announced its quarterly earnings results on Wednesday, June 1st. The healthcare company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.07). UiPath had a negative net margin of 42.95% and a negative return on equity of 18.47%. The firm had revenue of $245.07 million for the quarter, compared to analysts’ expectations of $225.37 million. During the same period in the previous year, the company earned ($0.81) EPS. The company’s quarterly revenue was up 31.6% on a year-over-year basis. On average, analysts expect UiPath to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
UiPath Trading Down 2.5 %
Shares of NASDAQ PATH opened at $16.52 on Tuesday. UiPath has a 12 month low of $13.66 and a 12 month high of $65.60. The firm has a market capitalization of $9.00 billion, a PE ratio of -21.45 and a beta of 0.09. The firm has a fifty day simple moving average of $19.48 and a two-hundred day simple moving average of $21.92.
Wall Street Analyst Weigh In
Several research analysts have commented on the stock. Oppenheimer decreased their price objective on shares of UiPath from $35.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, June 2nd. Barclays decreased their price objective on shares of UiPath from $36.00 to $25.00 in a report on Friday, May 20th. Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 price target on shares of UiPath in a research note on Thursday, July 7th. Evercore ISI decreased their price target on shares of UiPath from $28.00 to $23.00 in a research note on Thursday, June 2nd. Finally, Cowen decreased their price target on shares of UiPath from $43.00 to $27.00 in a research note on Friday, May 27th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $36.06.
Insider Buying and Selling
In related news, Director Kimberly Hammonds sold 2,521 shares of the firm’s stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $18.70, for a total value of $47,142.70. Following the transaction, the director now owns 100,662 shares of the company’s stock, valued at $1,882,379.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other UiPath news, CAO Hitesh Ramani sold 22,800 shares of UiPath stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $20.70, for a total transaction of $471,960.00. Following the transaction, the chief accounting officer now owns 426,799 shares of the company’s stock, valued at $8,834,739.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kimberly Hammonds sold 2,521 shares of UiPath stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $18.70, for a total transaction of $47,142.70. Following the transaction, the director now directly owns 100,662 shares in the company, valued at approximately $1,882,379.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 125,321 shares of company stock valued at $2,589,103. 31.88% of the stock is owned by insiders.
Hedge Funds Weigh In On UiPath
Large investors have recently added to or reduced their stakes in the company. American International Group Inc. purchased a new position in UiPath during the second quarter valued at approximately $74,000. Point72 Hong Kong Ltd lifted its holdings in UiPath by 28,088.9% during the second quarter. Point72 Hong Kong Ltd now owns 5,074 shares of the healthcare company’s stock valued at $92,000 after purchasing an additional 5,056 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in UiPath during the first quarter valued at approximately $108,000. Advisors Asset Management Inc. lifted its holdings in UiPath by 74.4% during the first quarter. Advisors Asset Management Inc. now owns 6,495 shares of the healthcare company’s stock valued at $140,000 after purchasing an additional 2,771 shares in the last quarter. Finally, Captrust Financial Advisors lifted its holdings in UiPath by 160.7% during the first quarter. Captrust Financial Advisors now owns 7,133 shares of the healthcare company’s stock valued at $154,000 after purchasing an additional 4,397 shares in the last quarter. Hedge funds and other institutional investors own 52.19% of the company’s stock.
About UiPath
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.